

TABLE II—NOCs APPROVED \* FROM 05/01/2021 TO 05/31/2021—Continued

Case No.	Received date	Commencement date	If Amendment, type of amendment	Chemical substance
P-17-0360A ..	05/05/2021	02/01/2021	Multiple CASRN submitted on single NOC.	(S) 2-propanol, 1-amino-,compd. with.alpha.-sulfo-.omega.-(octyloxy)poly(oxy-1,2-ethanediyl)(1:1).
P-18-0041 .....	05/07/2021	03/09/2021	N .....	(S) 2,5-furandione, polymer with 2-ethyl-2-(hydroxymethyl)-1,3-propanediol, 3a,4,5,6,7,7a-hexahydro-4,7-methano-1h-inden-5(or 6)-yl ester, ester with 2,3-dihydroxypropyl neodecanoate.
P-18-0334 .....	05/20/2021	04/22/2021	N .....	(S) Propanedioic acid, 1,3-dihexyl ester.
P-18-0335 .....	05/20/2021	04/22/2021	N .....	(S) Propanedioic acid, 1,3-dicyclohexyl ester.
P-18-0336 .....	05/25/2021	05/11/2021	N .....	(S) Propanedioic acid, 2,2-bis(hydroxymethyl)-, 1,3-dihexyl ester.
P-18-0351 .....	05/10/2021	05/04/2021	N .....	(G) Acrylic acid, tricyclo alkyl ester.
P-20-0036 .....	05/18/2021	05/14/2021	N .....	(S) Carbonic acid, di(lithium-6li) salt.
P-20-0159 .....	04/30/2021	04/06/2021	N .....	(G) Phenoxathiinium, 10-phenyl, 5-alkyl-2-alkyl-4-(2,4,6-substituted tri-carbomonocycle, hetero-acid)benzenesulfonate (1:1).
P-21-0018 .....	04/30/2021	04/06/2021	N .....	(G) Sulfonium, triphenyl-, heterocyclic compound-carboxylate (1:1).

\* The term 'Approved' indicates that a submission has passed a quick initial screen ensuring all required information and documents have been provided with the submission.

In Table III of this unit, EPA provides the following information (to the extent such information is not subject to a CBI claim) on the test information that has been received during this time period: The EPA case number assigned to the test information; the date the test information was received by EPA, the type of test information submitted, and chemical substance identity.

TABLE III—TEST INFORMATION RECEIVED FROM 05/01/2021 TO 05/31/2021

Case No.	Received date	Type of test information	Chemical substance
P-16-0289 .....	05/26/2021	Particle Size Analysis .....	(G) Semi-aromatic polyamide.
P-16-0462 .....	05/10/2021	Quarter 1 Metals Report .....	(G) Silane-treated aluminosilicate.
P-16-0543 .....	05/12/2021	Exposure Monitoring Report .....	(G) Halogenophosphoric acid metal salt.
P-18-0160 .....	05/20/2021	14-Day Range-Finding Study and Combined Repeated Dose Toxicity Study with Reproductive-Developmental Toxicity Test.	(G) Heteropolycyclic, halo substituted alkyl substituted- diaromatic amino substituted carbomonocycle, halo substituted alkyl substituted heteropolycyclic, tetraaromatic metalloid salt (1:1).
P-20-0044 .....	05/26/2021	Freshwater Algal Growth Inhibition Test (OECD Test Guideline 201).	(S) 1-propanamine, 3-methoxy-n,n-dimethyl.
P-20-0073 .....	05/11/2021	Ready Biodegradability Manometric Respirometry Tests (OECD Test Guideline 301F), Assessment of Aerobic Degradability in Seawater, Assessment of the 10 day LC50 Toxicity to the Marine Crustacean Corophium Volutator (OSPARCOM Part A Method), Assessment of the Toxicity to the Marine fish Cyprinodon Variegatus (OSPAR Limit Test), Assessment of the 72 Hour EC(r)50 toxicity to the Marine Unicellular Algae Skeletonema sp., and Manufacture Process Description.	(G) 2,5-furandione, reaction products with alkylamine, 1-octanol and polyethylene glycol alkoxy-ether, acetates (salts).

If you are interested in information that is not included in these tables, you may contact EPA's technical information contact or general information contact as described under **FOR FURTHER INFORMATION CONTACT** to access additional non-CBI information that may be available.

Authority: 15 U.S.C. 2601 *et seq.*

Dated: June 9, 2021.

**Pamela Myrick,**

*Director, Project Management and Operations Division, Office of Pollution Prevention and Toxics.*

[FR Doc. 2021-12504 Filed 6-14-21; 8:45 am]

**BILLING CODE 6560-50-P**

**ENVIRONMENTAL PROTECTION AGENCY**

[EPA R09-2021-08; FRL-10024-41-Region 9]

**Notice of Proposed CERCLA Section 122(h)(1) Settlement for Cost Recovery of Past Response Costs at the Santa Clara Waste Water Treatment Plant Emergency Removal Site, Santa Paula, California**

**AGENCY:** Environmental Protection Agency (EPA).

**ACTION:** Notice of proposed settlement; request for public comment.

**SUMMARY:** In accordance with the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended ("CERCLA"), notice is hereby given that the Environmental Protection Agency ("EPA"), has entered into a proposed settlement, embodied in a CERCLA Section 122(h)(1) Settlement for Cost Recovery ("Settlement Agreement"), with Santa Clara Waste Water Company ("SCWW"). Under the Settlement Agreement, SCWW agrees to pay some of EPA's past response costs at the Santa Clara Waste Water Treatment Plant Emergency Removal Site, Santa Paula,

California (“Site”) in Santa Paula, California.

**DATES:** Comments must be received on or before July 15, 2021.

**ADDRESSES:** The proposed settlement agreement is available for public inspection at <https://cumulis.epa.gov/supercpad/cursites/csitinfo.cfm?id=0900238>. Comments on the Settlement Agreement should be submitted in writing to Rebekah Reynolds at [reynolds.rebekah@epa.gov](mailto:reynolds.rebekah@epa.gov). Comments should reference the Santa Clara Waste Water Treatment Plant Emergency Removal Site and the EPA Docket Number for the Settlement Agreement, EPA R9–2021–08. If for any reason you are not able to submit a comment by email, please contact Ms. Reynolds at (415) 972–3916 to make alternative arrangements for submitting your comment. EPA will post its response to any comments at [https://response.epa.gov/site/site\\_profile.aspx?site\\_id=9634](https://response.epa.gov/site/site_profile.aspx?site_id=9634), EPA’s website for the Site.

**FOR FURTHER INFORMATION CONTACT:** Rebekah Reynolds, Assistant Regional Counsel (ORC–3), Office of Regional Counsel, U.S. EPA Region IX, 75 Hawthorne Street, San Francisco, CA 94105; Email: [reynolds.rebekah@epa.gov](mailto:reynolds.rebekah@epa.gov); Phone: (415) 972–3916.

**SUPPLEMENTARY INFORMATION:** Notice of this proposed administrative settlement is made in accordance with Section 122(i) of CERCLA. The Settlement Agreement concerns past response costs incurred by EPA to perform oversight at the Site. Under the Settlement Agreement, SCWW agrees to pay EPA \$111,000 for past response costs. The Settlement Agreement includes a covenant not to sue SCWW for past response costs pursuant to Section 107(a) of CERCLA. EPA will consider all comments received on the Settlement Agreement in accordance with the **DATES** and **ADDRESSES** sections of this Notice and may modify or withdraw its consent to the Settlement Agreement if comments received disclose facts or considerations that indicate that the settlement is inappropriate, improper, or inadequate.

Dated: June 7, 2021.

**Enrique Manzanilla,**

Director, Superfund Division, EPA Region 9.  
[FR Doc. 2021–12459 Filed 6–14–21; 8:45 am]

**BILLING CODE 6560–50–P**

## FEDERAL DEPOSIT INSURANCE CORPORATION

### Sunshine Act Meeting

**TIME AND DATE:** 10:00 a.m. on Tuesday, June 15, 2021.

**PLACE:** The meeting is open to the public. Out of an abundance of caution related to current and potential coronavirus developments, the public’s means to observe this Board meeting will be via a Webcast live on the internet and subsequently made available on-demand approximately one week after the event. Visit <http://fdic.windrosemedia.com> to view the live event. Visit <http://fdic.windrosemedia.com/index.php?category=FDIC+Board+Meetings> after the meeting. If you need any technical assistance, please visit our Video Help page at: <https://www.fdic.gov/video.html>.

Observers requiring auxiliary aids (e.g., sign language interpretation) for this meeting should call 703–562–2404 (Voice) or 703–649–4354 (Video Phone) to make necessary arrangements.

**STATUS:** Open.

**MATTERS TO BE CONSIDERED:** Pursuant to the provisions of the “Government in the Sunshine Act” (5 U.S.C. 552b), notice is hereby given that the Federal Deposit Insurance Corporation’s Board of Directors will meet in open session to consider the following matters:

#### Summary Agenda

No substantive discussion of the following items is anticipated. These matters will be resolved with a single vote unless a member of the Board of Directors requests that an item be moved to the discussion agenda.

Disposition of Minutes of a Board of Directors’ Meeting Previously Distributed.

*Memorandum and resolution re:* Final Policy Statement Regarding Minority Depository Institutions.

*Memorandum and resolution re:* Notice of Proposed Rulemaking on Real Estate Lending Standards.

Status of report of actions taken pursuant to authority delegated by the Board of Directors.

#### Discussion Agenda

*Memorandum and resolution re:* Establishment of the FDIC Advisory Council on Innovation.

*Briefing:* Restoration Plan Semiannual Update.

**CONTACT PERSON FOR MORE INFORMATION:** Requests for further information concerning the meeting may be directed to Ms. Debra A. Decker, Deputy

Executive Secretary of the Corporation, at 202–898–8748.

Dated at Washington, DC, on June 10, 2021.  
*Federal Deposit Insurance Corporation.*

**James P. Sheesley,**

*Assistant Executive Secretary.*

[FR Doc. 2021–12589 Filed 6–11–21; 11:15 am]

**BILLING CODE 6714–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

[Docket No. CDC–2021–0060]

#### Advisory Committee on Immunization Practices (ACIP)

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of meeting and request for comment.

**SUMMARY:** In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention (CDC), announces the following meeting of the Advisory Committee on Immunization Practices (ACIP). This meeting is open to the public. The meeting will be webcast live via the World Wide Web. Time will be available for public comment.

**DATES:** The meeting will be held on June 18, 2021, from 11:00 a.m. to 5:00 p.m., EDT (dates and times subject to change), see the ACIP website for updates: <http://www.cdc.gov/vaccines/acip/index.html>. The public may submit written comments from June 15, 2021 through June 18, 2021.

**ADDRESSES:** You may submit comments, identified by Docket No. CDC–2021–0060 by any of the following methods:

- *Federal eRulemaking Portal:* <https://www.regulations.gov>. Follow the instructions for submitting comments.

- *Mail:* Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS H24–8, Atlanta, Georgia 30329–4027, Attn: June 18, 2021 ACIP Meeting.

*Instructions:* All submissions received must include the Agency name and Docket Number. All relevant comments received in conformance with the <https://www.regulations.gov> suitability policy will be posted without change to <https://www.regulations.gov>, including any personal information provided. For access to the docket to read background documents or comments received, go to <https://www.regulations.gov>.

**FOR FURTHER INFORMATION CONTACT:** Stephanie Thomas, ACIP Committee